

演講嘉賓簡介

Tse Wen Chang 張子文

Founder and President, Immunwork, Inc., Taipei, Taiwan

Distinguished Visiting Chair, Genomics Research Center, Academia Sinica

Dr. Chang cofounded Tanox in Houston, Texas in 1986 and invented in 1987 the anti-IgE therapy, leading to the development of talizumab, omalizumab (Xolair), and ligelizumab. Xolair has been approved for treating severe allergic asthma and chronic spontaneous urticaria. While in Academia Sinica, his group developed FB825 and UB221, which have been respectively licensed to two companies in Taiwan for clinical development. Dr. Chang is now leading Immunwork, Inc. to develop new drugs with both targeting and effector moieties for applications in various diseases.

Education

- National Tsing Hua University, Chemistry B.S., M.S. 1966-72
- Harvard University, Cell & Developmental Biology Ph.D. 1973-77
- M.I.T., Immunology Postdoctoral Research 1977-80

Professional experience

- Ortho Pharmaceutical Corp (Raritan, NJ), J & J – Supervisor, Cellular Immunology 1980-81
- Centocor, Inc (Malvern, PA) – Research Director, V.P. Research 1981-85
- Baylor College of Medicine (Houston) – Prof. Molecular Virology 1986-91
- Tanox, Inc (Houston) – Cofounder, V.P. R&D, Board Director 1986-2007
- National Tsing Hua University, Life Science – Prof., Dean 1996-2006
- Development Center for Biotechnology – President 2000-03
- Academia Sinica, Genomics Research Center – Distinguished Res Fellow 2006-15

Research interests

- Developing therapeutic antibodies for targeting IgE and IgE-B cells, for treating allergy, asthma, chronic urticaria, etc.
- Developing T-E pharmaceuticals with targeting and effector moieties for improved efficacy and safety, for applications in oncology, autoimmune, CNS, and infectious diseases, and in other severe conditions

Honors

- Honorary Fellow Award, American College of Allergy Asthma and Immunology (ACAAI) 2004
- Nature Biotechnology's shortlist of personalities who made the most significant contribution to biotech in the past 10 years. 2006
- Honorary Fellow Award, American Academy of Allergy Asthma and Immunology (AAAAI) 2007
- Prize in Biomedical Sciences, the World Academy of Science (TWAS) 2014

2017 Taiwan PharmaVision

從靶點到授權，推動台灣生技接軌全球



科睿唯安